April 2, 2019
A research team led by KI faculty member Angela Koehler developed a strategy for reducing the activity of Myc, one of the most common, but notoriously difficult to target cancer-promoting genes. Scientists have tried–and failed–for decades to develop drugs that block the Myc protein, which is overexpressed in about 70% of cancers. In a study appearing in Cell Chemical Biology, researchers discovered a new compound that ties up Myc's binding partner, Max. The compound stabilizes bonds between two Max molecules, leaving unpartnered Myc molecules to be broken down within cells. The compound, which the study found to suppress tumor growth in mouse models, has been licensed by Kronos Bio for further study and development. Read more.